Treatment of Chronic Hepatitis C with a-Interferon: An Analysis of the Literature

Hepato-Gastroenterology

Volumn 43, Issue 12, 1996, Pages 1544-1556

  Niederau, Claus ^a   Heintges, Tobias ^a   Häussinger, Dieter ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Antiviral therapy; Hepatitis C virus; Interferon; Liver cirrhosis; Meta analysis

Indexed keywords

ALANINE AMINOTRANSFERASE; LYMPHOBLAST INTERFERON; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT ALPHA2C INTERFERON;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHRONIC HEPATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; HEPATITIS C; HEPATITIS NON A NON B; HUMAN; HUMAN TISSUE; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SUBCUTANEOUS DRUG ADMINISTRATION;

ALANINE TRANSAMINASE; CHRONIC DISEASE; HEPATITIS C; HUMANS; INTERFERON-ALPHA; LIVER CIRRHOSIS; REGRESSION ANALYSIS;

EID: 0030458737     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (73)

1. Sherlock DS. Viral hepatitis C. Curr Opin Gastroenterol 1993;9:341-348.
2. Peters M. Mechanisms of action of interferon. Semin Liver Dis 1989;9:5-9.
3. Tine F, Magrin S, Craxi A, and Pagliaro L. Interferon for non-A, non-B chronic hepatitis. J Hepatol 1991; 13:192-99.
4. Sacks HS, Berner J, Reitman D, et al. Meta-analysis of randomized clinical trials. N Engl J Med 1987;316:450-55.
5. Alberti A, Chemello L, Bonetti P, Casarin C, Diodati G, Cavalletto L, Cavalletto D, and The TVVH Study Group. Treatment with interferon(s) of community-acquired chronic hepatitis and cirrhosis type C. J Hepatol 1993;17:S123-S126.
6. Brower JF and the Benelux Multicentre Trial Study Group. Benelux multicentre trial of alpha interferon treatment for chronic hepatitis C: standard vs high dose treatment monitored by biochemical and virological markers (interim analysis). Gut 1993; 17:S119-S120.
7. Bosch O, Tapia L, Quiroga JA, Carreno V. An escalating dose regime of recombinant interferon α-2a in the treatment of chronic hepatitis C. J Hepatol 1993; 17:146-149.
8. Brillanti S, Ricci P, Paparo GF, Miglioli M, Barbara L. Efficacy of different treatments with α interferon in chronic sporadic hepatitis C. Hepatology 1991; 14:A200.
9. Camps J, Castilla A, Riezu-Boj JI. Effectiveness of long-term lymphoblastoid interferon treatment in chronic hepatitis C (CHC). J Hepatol 1990;11:S15.
10. Camps J, Crisostomo S, Garcua-Granero M, Riezu-Boj JI, Civeira MP, Prieto J. Prediction of the response of chronic hepatitis C to interferon a: a statistical analysis of pretreatment variables. Gut 1993; 34:1714-1717.
11. Camps J, Castilla A, Ruiz J, Civeira MP, Prieto J. Randomised trial of lymphoblastoid α interferon in chronic hepatitis C: Effects on inflammation, fibrogenesis and viremia. J Hepatol 1993;17:390-396.
12. Carreño V, Trepo C, Gerken G, Barcena A, Bar Meir S, Desmet V, Ryff JC. A double blind placebo controlled trail of treatment of chronic hepatitis NANB with recombinant interferon α-2a. Hepatology 1992; 16:A75.
13. Castilla A, Camps-Bansell J, Civeira MP, Prieto J. Lymphoblastoid α-interferon for chronic hepatitis C: a randomized controlled study. Am J Gastroenterol 1993; 88: 233-239.
14. Causse X, Godinot H, Chevalier M, Chossegros P, Zoulim F, Ouzan D, et al. Comparison of 1 or 3 MU of interferon alpha-2b and placebo in patients with chronic non-A non-B hepatitis. Gastroenterology 1991;101:497-502.
15. Cerini R, Cozzolino G, Morante R, Lucariello A, De Rosa ML, Cacciatore F. Relatively high dose for twelve months recombinant a interferon treatment in chronic hepatitis C: a randomized controlled study. Hepatology 1991;14:A70.
16. Colombo M, Rumi MG, Marcelli R, Ibba M, Parravicini ML, Donato MF, Ninno ED. Randomized controlled trial of recombinant interferon α in patients with chronic hepatitis C. Hepatology 1991;14:A73.
17. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC, Perillo RP, Carey W, et al. Treatment of chronic hepatitis C with recombinant interferon α. A mulicenter randomized controlled trial. New Engl J Med 1989;321:1501-1506.
18. De Conca V, Mornese A, Michetti P. Treatment of chronic NANB (type C) hepatitis with recombinant interferon alpha-2b. Preliminary clinical results. Gastroenterology 1990; 98:A581.
19. Di Bisceglie A, Martin P, Kasianides C, Lisker-Melman M, Murray L, Waggoner J, Goodman Z, et al. Recombinant interferon alpha therapy for chronic hepatitis C. N Engl J Med 1989;321:1506-1510.
20. Douglas D, Rakela J, Ju Lin H, Hollinger FB, Taswell HF, Czaja AJ, Gross JB, et al. Randomized controlled trial of recombinant alpha-2a-interferon for chronic hepatitis C. Dig Dis Sci 1993;38:601-607.
21. Farrell G, Lin R, Schoeman M, Craig P, Mac Donald J, Batey RG. Interferon α-2b for chronic active hepatitis C: Interim results of an australian trial. Proceedings of the international symposion on the management of chronic viral hepatitis. Adelphi Communications, Macclesfield, UK, 1989:24.
22. Febo di G, Brillanti S, Calabrese C, Miglioli M, Cavalli G, Barbara L. Alpha interferon therapy in chronic hepatitis C patients with and without liver disease. Hepatology 1992;16: A200.
23. Feinman SV, Willems B, Minuk G, Heathcote JE, Bailey R, Scully L, Steinbrecher U, et al. Treatment of chronic non-A non-B hepatitis (NANB/H) blood related and sporadic with recombinant interferon A (IFN). Controlled, multi-centre study from Canada. Hepatology 1991;14:71A.
24. Ferenci P, Vogel W, Hentschel E, Pristautz H, Fiedler R, Judmaier G, Krejs GJ, Gangl A. One year interferon alpha treatment of chronic hepatitis NANB. Hepatology 1991;14: A72.
25. Findor J, Perez V, Tanno H. Recombinant interferon alpha-2b in the treatment of chronic non-A non-B (NANB) hepatitis. IASL Meeting Abstract Book. Gold Coast Australia 1990:76.
26. Garcia-Buey L, Garcia-Monzon C, Garcia-Sanchez A, Pajares JM, Moreno-Otero R. Treatment of chronic NANB viral hepatitis with recombinant interferon α-2b. Preliminary clinical and immunologic results. Proceedings of the international symposion on the management of chronic viral hepatitis. Adelphi Communications, Macclesfield, UK, 1989:26.
27. Gomez-Rubio M, Porres JC, Castillo J, Quiroga JA, Moreno A, Carreno V. Prolonged treatment (18 months) of chronic hepatitis C with recombinant alpha-interferon in comparison with a control group. J Hepatol 1990;11:S63-S67.
28. Ideo G, Bellati G, Pedraglio E. One year therapy of non-A non-B/C chronic hepatitis with recombinant alpha-2a-interferon or lymphoblastoid alphα-interferon. J Hepatol 1990;11: S31.
29. Jacyna MR, Brooks MG, Loke RHT, Main J, Murray-Lyon IM, Thomas HC. Randomized controlled trial of interferon alpha (lymphoblastoid interferon) in chronic non-A non-B hepatitis. Br Med J 1989;298:80-82.
30. Jouet P, Roudot-Thoroval F, Dhumeaux D, Metreau JM, Le groupe francais pour l'itude du traitement des hipatites chroniques NANB/C. Comparative efficacy of interferon a in cirrhotic and noncirrhotic patients with non-A, non-B hepatitis. Gastroenterology 1994;106:686-690.
31. Kagawa T, Morizane T, Saito H, Miyaguchi S, Tsunematsu S, Tada S, Guevara FM, et al. A randomized, controlled trial of weekly administration of lymphoblastoid interferon in patients with chronic hepatitis C. J Hepatol 1993;17:91-96.
32. Kakumu S, Arao M, Yoshioka K, Hayashi H, Kusakabe A, Hirofuji H, Kawabe M. Recombinant human alpha-interferon therapy for chronic non-A non-B hepatitis: second report. Am J Gastroenterol 1990; 85:655-659.
33. Lau JYN, Davis GL, Kniffen J, Qian KP, Urdea MS, Chan CS, Mizokami M, Neuwald PD, Wilber JC. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet 1993;341:1501-1504.
34. Lin R, Shoeman M, Craig P, et al. Randomized controlled trial of interferon alpha-2a for chronic active hepatitis non-A non-B: biochemical and histological evidence of remission. Hepatology 1989;10:A646.
35. Lin R, Zimmermann M, Roach E, Farell G. Alpha-interferon 2b in the treatment of chronic active hepatitis c: interim report of the first multicentre australian trial. Hepatology 1992;16:A75.
36. Marcellin P, Boyer N, Giostra E, Degott C, Couroche AM, Degos F, Coppere H, et al. Recombinant human alpha-interferon in patients with chronic non-A, non-B hepatitis: a multicenter randomized controlled trial from France. Hepatology 1991;13:393-397.
37. Marcellin P, Pouteau M, Boyer N, Degos F, Martinot-Peignoux M, Degott C, Erlinger S. Absence of efficacy of an increasing dosage schedule of the response rate during and after recombinant alpha interferon therapy in chronic hepatitis C. Hepatology 1991; 14:71A.
38. Mazzella G, Villanova N, Bazzoli F. Preliminary results of a randomized controlled trial with human lymphoblastoid interferon in chronic non-A non-B hepatitis. Ital J Gastroenterol 1990;22:175.
39. Mitreau JM, The French Group for the study of NANB/C chronic hepatitis treatment. Results of long term interferon treatment in non A non B/C chronic active hepatitis. Gut 1993;34:S112-S113.
40. Müller R, Baumgarten R, Markus R, Beckh KH, Loeschke K, Stremmel W, Niederau C, Wiedmann KH, Weber P. Long-term treatment with low doses of interferon alpha-2b (rIFNa2b) in patients with chronic non-a non-B (NANB) hepatitis: data of a multicenter randomized prospectively controlled trial. J Hepatol 1990;11:184.
41. Payen JL, Halimi A, Vinel JP, Combis JM, Voigt JJ, Pascal JP. Can chronic hepatitis C be healed by alpha interferon therapy? Hepatology 1993;18:249A.
42. Piazza M, Guadagnino V, Picciotto L. Multicenter study-on the treatment of chronic NANB hepatitis with recombinant human interferon alpha-2b. Proceedings of the International symposion on the management of chronic viral hepatitis. Adelphi Communications, Macclesfield, UK, 1989:31.
43. Portal I, Bourlinre M, Halfon P, Gerolami V, Khiri H, Cartouzou G, Garnier PP, et al. Predictive value of serum hepatitis C virus RNA levels during interferon a therapy. Gastroenterology 1994;106:A963.
44. Realdi G, Diodati G, Bonetti P, Scaccabarozzi S, Alberti A, Ruol A. Recombinant human interferon alpha-2a in community acquired non-A non-B chronic active hepatitis. Preliminary results of a randomized controlled trial. J Hepatol 1990;11:S68-S71.
45. Reichard O, Foberg U, Frydin A, Mattsson L, Norkrans G, Swnnerborg A, Wejstal R, et al. High sustained response rate and clearance of viremia in chronic hepatitis C after treatment with interfon alpha-2-b for 60 weeks. Hepatology 1994;19:280-285.
46. Saez-Royuela F, Porres JC, Moreno A, Castillo I, Martinez G, Galiana F, Carreẃo V. High doses of recombinant alpha-interferon or gamma-interferon for chronic hepatitis C: a randomized, controlled trial. Hepatology 1990;13:327-331.
47. Sangiovanni A, Spinzi GC, Bissoli F, Colombo E, Rainer H, Colli A, Casiraghi A, et al. Multicenter randomized trial with recombinant interferon alpha-2b in the treatment of chronic hepatitis C. Gastroenterology 1993; 104:A984.
48. Saracco G, Rosina F, Torrani-Cerenzia MR, Lattore V, Chiandussi L, Gallo V, Petrino R, et al. A randomized controlled trial of interferon alpha-2b as therapy for chronic non-A non-B hepatitis. J Hepatol 1990; 11:S43-S49.
49. Schvarcz R, Weiland O, Wejstal R. A randomized controlled open study of interferon alpha-2b treatment of chronic non-A non-B posttransfusion hepatitis: no correlation of outcome to presence of hepatitis C virus antibodies. Scand J Infect Dis 1989; 21:617-625.
50. Terrault N, Wilber J, Feinman SV. Response to interferon therapy predicted by changes in serum HCV-RNA titer early in treatment. Gastroenterology 1994; 106:A997.
51. Tobias H, Sherman A, Michaud J, Tepperman L. Effectiveness of high dose/long term a interferon therapy in chronic hepatitis C. Gastroenterology 1994;106:A999.
52. Torras J, Martinez-Cerezo FJ, Enriquez J, Buenestado J, Puig M, Boadas J, Portorreal R, Sancho FJ. Lymphoblastoid interferon in chronic hepatitis type C: Preliminary results of two dosage regimens. J Hepatol 1992;16:S50.
53. Tremolada F, Casarin C, Scaccabarozzi S. Randomized controlled trial of recombinant alpha-2a-interferon in chronic NANB posttransfusion hepatitis. J Hepatol 1990;11:S117.
54. Vandelli C, Renzo F, Palmisani L, Vecchi C, Floridia A, Spagnolo V. Long term alpha-2-b interferon therapy in chronic HCV infection. Hepatology 1993; 18:260A.
55. Varagona G, Brown D, Kibbler H, Scheuer P, Ashrafzadeh P, Sherlock S, McIntyre N, Dusheiko GM. Response, relapse and re-treatment rates and viraemia in chronic hepatitis C treated with alpha-2b-interferon: a phase III study. Eur J Gastro Hep 1992; 4:707-712.
56. Weiland O, Schvarcz R, Wejstal R, Norkrans G, Fryden A. Therapy of post-transfusion non-A non-B hepatitis with interferon alpha-2b: swedish experience. J Hepatol 1990;11:S57-S62.
57. Alberti A, Chemello L, Diodati G, Bonetti P, Pontisso P, Scaccabarozzi A, Realdi G. Treatment of chronic hepatitis C with different regimens of interferon alpha 2a. Hepatology 1992;16:A75.
58. Causse X, Godinot H, Ouzan D. Recombinant alpha-interferon for chronic non-A non-B hepatitis: optimal dose and factors associated with favourable response. Hepatology 1989;10:A643.
59. Cimino L, Nardone G, Citarella C, Perna E, Capuano G, Budillon G. Treatment of chronic hepatitis C with recombinant interferon alpha. Ital J Gastroenterol 1991;23:399-402.
60. Idea G, Bellati G, Pedraglio E, Altieri G. Recombinant alpha-2α-interferon (r-IFN), lymphoblastoid alpha-interferon (l-IFN) or no treatment for non-A non-B chronic active hepatitis (CAH): a prospective randomized controlled trial. Hepatology 1989;10:637.
61. Jacyna MR, Brooks G, Loke RHT. A controlled study of lymphoblastoid interferon in chronic non-A, non-B hepatitis. J Hepatol 1988;7:S42.
62. Jouet P, Roudot-Thoroval F, Dhumeaux D, Metreau JM. Treatment of NANB/C chronic active hepatitis by alpha interferon: comparison of response in cirrhotic and non-cirrhotic patients. J Hepatol 1992; 16:S50.
63. Marcellin P, Boyer N, Giostra E, Degott C, Degos F, Coppere H, Cales P, et al. Better efficacy of high dose versus low dose recombinant interferon alpha-2b treatment in chronic non-A non-B hepatitis. Hepatology 1989;10: A646.
64. Marcellin P, Pouteau M, Boyer N, Degos F, Martinot-Peignoux M, Degott C, Erlinger S, Benhamou JP. Treatment of chronic non-A non-B hepatitis with recombinant alpha-interferon: comparison between constant and increasing dosage. J Hepatol 1991;13:S49.
65. Mitreau JM, Calmus Y, Poupon R, Jouanolle H, Miguet JP, Brechot C, Cales P, et al. Twelve-month treatment, compared to 6-month treatment, does not improve the efficacy of alpha-interferon in NANB chronic active hepatitis. Hepatology 1991;14:A72.
66. Saiz-Royuela F, Porres JC, Carreẃo V. Treatment of chronic non-A non-B hepatitis with high doses of rIFN-alpha or rIFN-gamma. Hepatology 1991;13:327-31.
67. Torras J, Martinez-Cerezo FJ, Miralles F, Buenestado J, Puig M, Boadas J, Portorreal R, et al. Hepatitis C and lymphoblastoid interferon therapy: results. Gastroenterology 1993;104:A1010.
68. Sachs HS, Berrier J, Reitmann D. Meta-analysis of randomized clinical trials. N Engl J Med 1987;316:450-455.
69. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clin Trials 1986;7:177-188.
70. L'Abbi KA, Detsky AS, O'Rourke K. Meta-analysis in clinical research. Ann Int Med 1987;107:224-233.
71. Emerson JD, Burdirk E, Hoaglin DC, Mosteller F, Chalmers TC. An empirical study of the possible relations of treatment differences to quality scores in controlled randomized clinical trials. Controlled Clin Trials 1990; 11:339-352.
72. Okada S, Akahane Y, Suzuki H, Okamoto H, Mishiro S. The degree of variability in the amino terminal region of the E2/NS1 protein of hepatitis C virus correlates with responsiveness to interferon therapy in viremic patients. Hepatology 1992;16:619-624.
73. Yoshioka K, Kakumu S, Wakita T, Ishikawa T, Itoh Y, Takayanagi M, Higashi Y, et al. Detection of hepatitis C virus by polymerase chain reaction and response to interferon alpha therapy: relationship to genotypes of hepatitis C virus. Hepatology 1992;16: 293-299.